Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

SANTHERA PHARMACEUTICALS HOLDING AG

(SANN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/30/2021 12/01/2021 12/02/2021 12/03/2021 12/06/2021 Date
1.264(c) 1.28(c) 1.304(c) 1.314(c) 1.304(c) Last
96 446 139 519 72 451 97 692 69 035 Volume
+0.32% +1.27% +1.88% +0.77% -0.76% Change
More quotes
Estimated financial data (e)
Sales 2021 8,00 M 8,64 M 8,64 M
Net income 2021 -40,0 M -43,2 M -43,2 M
Net Debt 2021 - - -
P/E ratio 2021 -1,76x
Yield 2021 -
Sales 2022 53,0 M 57,2 M 57,2 M
Net income 2022 -36,0 M -38,9 M -38,9 M
Net Debt 2022 - - -
P/E ratio 2022 -1,98x
Yield 2022 -
Capitalization 54,7 M 59,2 M 59,1 M
Capi. / Sales 2021 6,84x
Capi. / Sales 2022 1,03x
Nbr of Employees 86
Free-Float 82,0%
More Financials
Company
Santhera Pharmaceuticals Holding AG (Santhera) is a Switzerland-based company engaged in the pharmaceutical sector. The Company is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The CompanyÔÇÖs products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's... 
Sector
Pharmaceuticals
Calendar
12/15 | 04:30amShareholder meeting
More about the company
Ratings of Santhera Pharmaceuticals Holding AG
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SANTHERA PHARMACEUTICALS HOLDING AG
01:31aSanthera to File Rolling New Drug Application for Duchenne Treatment to US FDA in Early..
MT
01:00aSanthera to Host Investor Conference Call — Looking Ahead to 2022
AQ
11/24Santhera's Board Calls Extraordinary General Meeting To Vote On Future Fundraisings
MT
11/24Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Appr..
DJ
11/24Santhera Pharmaceuticals Holding AG announced that it has received CHF 15 million in fu..
CI
11/23Santhera's Mid-Stage Trial For Duchenne Muscular Dystrophy Drug Shows Sustained Efficac..
MT
11/23Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completi..
AQ
11/17Santhera JV to Seek US FDA's New Drug Approval For Duchenne Muscular Dystrophy Treatmen..
MT
11/17Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchen..
DJ
11/17Santhera Pharmaceuticals and ReveraGen Biopharma Announces Successful FDA Pre-NDA Meeti..
CI
11/04Santhera Appoints Stephanie Brown as President North America and Member of the Executiv..
AQ
11/04Santhera Pharmaceuticals Holding AG Appoints Stephanie Brown as President North America..
CI
10/18SANTHERA PHARMACEUTICALS : H1 Loss Narrows As Operating Expenses Decline
MT
10/15Santhera Announces First Half-Year 2021 Financial Results and Updates on Corporate Prog..
DJ
10/13SANTHERA PHARMACEUTICALS : 2021 Santhera Interim Report
PU
More news
News in other languages on SANTHERA PHARMACEUTICALS HOLDING AG
01:31aSanthera déposera une demande d'autorisation de mise sur le marché d'un nouveau médicam..
01:01aSanthera lädt zu Investoren-Telefonkonferenz ein — Ausblick auf das Jahr 2022
11/24Santhera veut demander 20 millions de francs supplémentaires en décembre
11/24Santhera beruft nach positiven Daten aoGV ein und beantragt Kapitalerhöhungen
11/24Le conseil d'administration de Santhera convoque une assemblée générale extraordinaire ..
More news
Chart SANTHERA PHARMACEUTICALS HOLDING AG
Duration : Period :
Santhera Pharmaceuticals Holding AG Technical Analysis Chart | SANN | CH0027148649 | MarketScreener
Technical analysis trends SANTHERA PHARMACEUTICALS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 1,30 CHF
Average target price 6,50 CHF
Spread / Average Target 398%
EPS Revisions
Managers and Directors
Dario Eklund Chief Executive Officer
Andrew P. Smith Chief Financial Officer
Elmar J. Schnee Chairman
Martin Gertsch Vice Chairman
Philipp Gutzwiller Independent Director